The C-Reactive Protein (CRP) is synthesized by the liver in response to interleukin-6 and well known as one of the classical acute-phase reactants and as a marker of inflammation. It has recently been suggested that a marker of inflammation, along with serum cholesterol, may be critical component in the development and progression of atherosclerosis. A growing body of evidence has supported the idea that cardiovascular diseases including coronary heart disease, ischemic stroke, and acute myocardial infarction, develop, at least in part, because of a chronic low-level CRP of the vascular endothelium. Apparently, high-sensitivity CRP (hsCRP) is emerging as the strongest and most independent predictive risk factor for atherosclerosis and CVD. American Heart Association (AHA) and the Centers for Disease Control and Prevention (CDC) issued a statement regarding use of C reactive protein to assess risk of cardiovascular diseases. The highly sensitive C-Reactive Protein Rapid Test is a rapid chromatographic immunoassay for semi-quantitative detection of C-Reactive Protein in whole blood, serum or plasma specimens to aid in evaluating risks of cardiovascular disease.